2012 Annual Report - Prometic - Life Science, Inc.

More documents

Recommendations

Info

For the year ended December 31, 2011 Therapeutics Protein Technology Corporate Total Revenues $ 7 $ 17,582 $ - $ 17,589 Costs of goods sold - 1,854 - 1,854 Research and development expenses rechargeable - 1,351 - 1,351 Research and development expenses non-rechargeable 1,800 8,079 - 9,879 Administration and marketing expenses - 575 5,214 5,789 Loss on foreign exchange - - 140 140 Impairment of licenses and patents 48 20 - 68 Impairment of investment - 25 - 25 Loss on extinguishment of debt - - 387 387 Finance costs 53 207 1,103 1,363 Net profit (loss) (1,894) 5,471 (6,844) (3,267) Segmented information by operating segment b) Total assets by operating segments December 31, December 31, 2012 2011 Therapeutics $ 3,675 $ 2,867 Protein Technology 8,790 5,464 Corporate 10,526 361 The investment in an associated company is included in the corporate operating segment. c) Capital assets and licenses and patents by operating segments $ 22,991 $ 8,692 December 31, December 31, 2012 2011 Therapeutics $ 1,828 $ 1,865 Protein Technology 3,520 3,343 Corporate 31 40 PROMETIC LIFE SCIENCES INC. $ 5,379 $ 5,248 56
d) Acquisition of capital assets and licenses and patents by operating segments December 31, December 31, 2012 2011 Therapeutics $ 204 $ 301 Protein Technology 702 695 Corporate 5 30 e) Total liabilities by operating segments $ 911 $ 1,026 December 31, December 31, 2012 2011 Therapeutics $ 1,315 $ 1,910 Protein Technology 9,739 9,110 Corporate 6,118 6,240 Segmented information by geographic segment f) Total assets by geographic area $17,172 $17,260 December 31, December 31, 2012 2011 Canada $ 14,420 $ 3,450 United States 2,968 1,717 United Kingdom 5,603 3,525 g) Capital assets and licenses and patents by geographic area $ 22,991 $ 8,692 December 31, December 31, 2012 2011 Canada $ 1,978 $ 2,059 United States 1,569 1,566 United Kingdom 1,832 1,623 h) Acquisition of capital assets and licenses and patents by geographic area $ 5,379 $ 5,248 December 31, December 31, 2012 2011 Canada $ 209 $ 426 United States 169 356 United Kingdom 533 244 $ 911 $ 1,026 PROMETIC LIFE SCIENCES INC. 57
Page 1 and 2:
ANNUAL REPORT 2012 We believe in ou
Page 3 and 4:
We have + 14 + 28 applications and
Page 5 and 6:
WHO WE ARE ProMetic Life Sciences I
Page 7 and 8: On May 15, 2012, ProMetic received
Page 9 and 10: alliance for the manufacturing of o
Page 11 and 12: PROMETIC’S BUSINESS IS ORGANIZED
Page 17 and 18: MANAGEMENT’S DISCUSSION & ANALYSI
Page 19 and 20: Although the Company achieved its f
Page 21 and 22: During the year ended December 31,
Page 23 and 24: FOURTH QUARTER The following inform
Page 25 and 26: Following a consulting agreement en
Page 27 and 28: CONSOLIDATED STATEMENTS OF FINANCIA
Page 29 and 30: CONSOLIDATED STATEMENTS OF CHANGES
Page 31 and 32: NOTES TO CONSOLIDATED FINANCIAL STA
Page 33 and 34: The gain or loss arising on the dis
Page 35 and 36: n) Income taxes The Company uses th
Page 37 and 38: IFRS 12 Disclosure of Involvement w
Page 39 and 40: 11. CAPITAL ASSETS Leasehold Equipm
Page 41 and 42: 13. BANK AND OTHER LOANS 2012 2011
Page 43 and 44: (b) Other loans: 1) Loan for an ini
Page 45 and 46: purposes. Consequently, the loans w
Page 47 and 48: 2012 During the year ended December
Page 49 and 50: d) Stock-based compensation: The Co
Page 51 and 52: 22. CAPITAL DISCLOSURES December 31
Page 53 and 54: Fair value hierarchy Financial inst
Page 55 and 56: December 31, 2012 December 31, 2011
Page 57: The Company has tax losses which ar
Page 61 and 62: On March 7, 2013, the share purchas
Page 63 and 64: CORPORATE INFORMATION HEADQUARTERS
show all

2012 Annual Report - Prometic - Life Science, Inc.

Create successful ePaper yourself

Delete template?

Save as template?